Analysis of Fecal Metagenomics and Plasma Metabolomics Uncovers Alterations in Gut Microbiota and Plasma Metabolite Profiles in Rats Experiencing Diarrhea Induced by Abemaciclib - Scorecard - MDSpire
Advertisement
Analysis of Fecal Metagenomics and Plasma Metabolomics Uncovers Alterations in Gut Microbiota and Plasma Metabolite Profiles in Rats Experiencing Diarrhea Induced by Abemaciclib
Clinical Scorecard: Analysis of Fecal Metagenomics and Plasma Metabolomics Uncovers Alterations in Gut Microbiota and Plasma Metabolite Profiles in Rats Experiencing Diarrhea Induced by Abemaciclib
At a Glance
Category
Detail
Condition
Key Mechanisms
Target Population
Female patients undergoing treatment with abemaciclib for breast cancer
Care Setting
Key Highlights
Understanding gut microbiota alterations is crucial for developing effective treatment strategies.
Guideline-Based Recommendations
Diagnosis
Management
Monitor gastrointestinal side effects and adjust treatment as necessary.
Consider dietary adjustments or probiotics to support gut health.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Female patients with HR+/HER2− breast cancer receiving abemaciclib.
Diarrhea management is essential for maintaining treatment adherence and quality of life.
Clinical Best Practices
Implement strategies to modulate gut microbiota and metabolites, such as dietary changes or probiotics.
Conduct regular assessments of gastrointestinal health during treatment.
Clinical researchers from Roswell Park Comprehensive Cancer Center are among the experts invited to share insights and clinical best practices at the National Comprehensive Cancer Network (NCCN) 2026 Annual Conference March 27-29 in Orlando, Florida.
